sh-Oligopeptide-1 (Human EGF)
Also known as: rh-EGF, Epidermal growth factor (cosmetic)
sh-Oligopeptide-1 (Human EGF), also called rh-EGF or Epidermal growth factor (cosmetic), is a research peptide in the Growth-factor mimetic class. Human epidermal growth factor is a 53-amino-acid protein that binds EGFR, a receptor tyrosine kinase, triggering dimerisation, autophosphorylation and downstream MAPK and PI3K/Akt signalling.
For research use only.
Key Facts
- CAS
- 62253-63-8
- Molecular Weight (MW)
- ≈6.2 kDa (protein growth factor)
- Half-life
- Topical; systemic PK not applicable
- FDA status
- Not Approved
- Administration Route
- Topical
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- EGFR
Research summary
Recombinant or fragment EGF used in cosmetics as sh-oligopeptide-1. Topical cosmetic; injectable EGF is a different, unapproved proposition.
Peptide Library's sh-Oligopeptide-1 (Human EGF) profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Per cosmetic formulation
- Frequency
- —
- Cycle
- —
- Administration Route
- Topical
- Reconstitution Guide
- —
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. sh-Oligopeptide-1 (Human EGF) is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C270H401N73O83S7 |
|---|---|
| Molecular weight | ≈6.2 kDa (protein growth factor) |
| CAS number | 62253-63-8 |
| Half-life | Topical; systemic PK not applicable |
| Appearance | White lyophilized powder (recombinant protein) |
| Formulation | Topical Cream |
| PubChem CID | 177865760 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Human epidermal growth factor is a 53-amino-acid protein that binds EGFR, a receptor tyrosine kinase, triggering dimerisation, autophosphorylation and downstream MAPK and PI3K/Akt signalling. In wound and cosmetic models this drives keratinocyte migration and proliferation and fibroblast activity, the basis for its use in topical repair and anti-ageing formulations. The practical constraint is delivery: at roughly 6 kDa the intact protein is far above the size that passively crosses an intact stratum corneum, so meaningful penetration depends on formulation, carriers, or compromised barrier function. Claims about topical activity should be read against that limitation.
Origin
Recombinant EGF or cosmetic oligopeptide listing.
Targets
Studies
- Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy
- Epidermal growth factor receptor in asthma: A promising therapeutic target?
- Growth Hormone Modulation of Hepatic Epidermal Growth Factor Receptor Signaling
- Therapeutic Approaches for the Treatment of Epidermal Growth Factor Receptor Mutated Lung Cancer
- Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies
Regulatory & research status
sh-Oligopeptide-1 (Human EGF) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | OTC / Supplement |
| WADA (sport) | Permitted |
| Library classification | Research-Only |
Benefits
sh-Oligopeptide-1 (Human EGF) side effects
Side Effects
- Irritation
- Theoretical EGFR stimulation concerns
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Cosmetic peptides in this library are formulated into topical products; follow the product label rather than the reconstitution guidance above.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
sh-Oligopeptide-1 (Human EGF): frequently asked questions
What is sh-Oligopeptide-1 (Human EGF)?
Recombinant or fragment EGF used in cosmetics as sh-oligopeptide-1. Topical cosmetic; injectable EGF is a different, unapproved proposition.
How does sh-Oligopeptide-1 (Human EGF) work?
Human epidermal growth factor is a 53-amino-acid protein that binds EGFR, a receptor tyrosine kinase, triggering dimerisation, autophosphorylation and downstream MAPK and PI3K/Akt signalling. In wound and cosmetic models this drives keratinocyte migration and proliferation and fibroblast activity, the basis for its use in topical repair and anti-ageing formulations.
Is sh-Oligopeptide-1 (Human EGF) FDA approved?
No. sh-Oligopeptide-1 (Human EGF) is not approved by the FDA for any indication and is categorised as otc / supplement. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of sh-Oligopeptide-1 (Human EGF)?
Reported half-life for sh-Oligopeptide-1 (Human EGF) is Topical; systemic PK not applicable. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is sh-Oligopeptide-1 (Human EGF) banned in sport?
sh-Oligopeptide-1 (Human EGF) is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.
What peptides are similar to sh-Oligopeptide-1 (Human EGF)?
Compounds most often compared with sh-Oligopeptide-1 (Human EGF) include Acetyl Hexapeptide-8, Acetyl Octapeptide-3, Acetyl Tetrapeptide-3 and AHK-Cu. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy — Expert Opin Investig Drugs, 2024External reference
- Epidermal growth factor receptor in asthma: A promising therapeutic target? — Respir Med, 2023External reference
- Growth Hormone Modulation of Hepatic Epidermal Growth Factor Receptor Signaling — Trends Endocrinol Metab, 2021External reference
- Therapeutic Approaches for the Treatment of Epidermal Growth Factor Receptor Mutated Lung Cancer — Curr Cancer Drug Targets, 2018External reference
- Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies — J Am Heart Assoc, 2017External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This sh-Oligopeptide-1 (Human EGF) profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track sh-Oligopeptide-1 (Human EGF) research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →